Cimerli, a biosimilar interchangeable with Lucentis, will launch in the United States on Oct. 3, according to a press release from Coherus BioSciences.
The FDA approved Cimerli (ranibizumab-eqrn) in August after meeting standards of biosimilarity and interchangeability to Lucentis (ranibizumab, Genentech). It is indicated for patients with neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy and myopic choroidal neovascularization.
“With the upcoming launch of Cimerli, retina specialists, patients and